[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 11 of about 11
1. Half E, Bercovich D, Rozen P: Familial adenomatous polyposis. Orphanet J Rare Dis; 2009;4:22
SciCrunch. KEGG: Data: Disease Annotation .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Familial adenomatous polyposis (FAP) is characterized by the development of many tens to thousands of adenomas in the rectum and colon during the second decade of life.
  • Most patients are asymptomatic for years until the adenomas are large and numerous, and cause rectal bleeding or even anemia, or cancer develops.
  • A less aggressive variant of FAP, attenuated FAP (AFAP), is characterized by fewer colorectal adenomatous polyps (usually 10 to 100), later age of adenoma appearance and a lower cancer risk.
  • In a subset of individuals, a MUTYH mutation causes a recessively inherited polyposis condition, MUTYH-associated polyposis (MAP), which is characterized by a slightly increased risk of developing CRC and polyps/adenomas in both the upper and lower gastrointestinal tract.
  • Presymptomatic and prenatal (amniocentesis and chorionic villous sampling), and even preimplantation genetic testing is possible.
  • Patients with progressive tumors and unresectable disease may respond or stabilize with a combination of cytotoxic chemotherapy and surgery (when possible to perform).
  • Adjunctive therapy with celecoxib has been approved by the US Food and Drug Administration and the European Medicines Agency in patients with FAP.
  • Individuals with FAP carry a 100% risk of CRC; however, this risk is reduced significantly when patients enter a screening-treatment program.

  • Genetic Alliance. consumer health - Familial Adenomatous Polyposis (FAP).
  • Genetic Alliance. consumer health - Familial Polyposis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Gastroenterol. 1993 Dec;17(4):343-7, discussion 347-8 [8308223.001]
  • [Cites] Hum Mutat. 1994;3(2):121-5 [8199592.001]
  • [Cites] Hum Genet. 1994 Nov;94(5):543-8 [7959691.001]
  • [Cites] N Engl J Med. 1995 Mar 30;332(13):839-47 [7661930.001]
  • [Cites] Ann Surg. 1995 Aug;222(2):120-7 [7639579.001]
  • [Cites] Am Fam Physician. 1995 Sep 15;52(4):1210 [7668210.001]
  • [Cites] Surgery. 1996 Jun;119(6):615-23 [8650601.001]
  • [Cites] Br J Surg. 1996 Jun;83(6):769-70 [8696735.001]
  • [Cites] Br J Surg. 1996 Jul;83(7):885-92 [8813770.001]
  • [Cites] J Med Genet. 1996 Jul;33(7):540-3 [8818937.001]
  • [Cites] Br J Surg. 1996 Nov;83(11):1578-80 [9014679.001]
  • [Cites] AJR Am J Roentgenol. 1997 Aug;169(2):465-72 [9242755.001]
  • [Cites] Ann Surg. 1997 Oct;226(4):514-9; discussion 519-21 [9351719.001]
  • [Cites] Arch Dis Child. 1997 Nov;77(5):431-5 [9487968.001]
  • [Cites] Am J Hum Genet. 1998 Mar;62(3):736-7 [9497250.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Apr;8(4 Pt 2):353-60 [10207640.001]
  • [Cites] Am J Hum Genet. 1999 Sep;65(3):902-9 [10441594.001]
  • [Cites] Nucleic Acids Res. 1999 Sep 15;27(18):3638-44 [10471731.001]
  • [Cites] Fam Cancer. 2006;5(3):213-20 [16998666.001]
  • [Cites] Fam Cancer. 2006;5(3):227-35 [16998668.001]
  • [Cites] Fam Cancer. 2006;5(3):241-60; discussion 261-2 [16998670.001]
  • [Cites] Fam Cancer. 2006;5(3):275-85; discussion 287-8 [16998673.001]
  • [Cites] Gastrointest Endosc. 2006 Oct;64(4):530-7 [16996344.001]
  • [Cites] Genet Med. 2006 Nov;8(11):697-703 [17108761.001]
  • [Cites] Reprod Biomed Online. 2006 Nov;13(5):707-11 [17169185.001]
  • [Cites] Mol Hum Reprod. 2007 Feb;13(2):95-101 [17114207.001]
  • [Cites] Am J Gastroenterol. 2007 Jun;102(6):1284-90 [17355417.001]
  • [Cites] Hum Mutat. 2007 Oct;28(10):985-92 [17486639.001]
  • [Cites] Genet Test. 2007 Fall;11(3):315-20 [17949294.001]
  • [Cites] Gastrointest Endosc. 2008 Jan;67(1):61-7 [18155426.001]
  • [Cites] Clin Gastroenterol Hepatol. 2008 Feb;6(2):180-5 [18237868.001]
  • [Cites] Fam Cancer. 2008;7(1):27-39 [17999161.001]
  • [Cites] Gut. 2008 May;57(5):704-13 [18194984.001]
  • [Cites] Curr Protoc Hum Genet. 2006 Aug;Chapter 10:Unit 10.8 [18428386.001]
  • [Cites] Endoscopy. 2008 May;40(5):437-42 [18398783.001]
  • [Cites] Am J Surg. 2008 Jun;195(6):741-8 [18436175.001]
  • [Cites] Clin Chem. 2008 Jul;54(7):1132-40 [18487285.001]
  • [Cites] Pathol Res Pract. 2008;204(7):479-90 [18538487.001]
  • [Cites] Ann Surg Oncol. 2008 Sep;15(9):2439-50 [18612695.001]
  • [Cites] Eur J Cancer. 2008 Nov;44(16):2404-10 [18706807.001]
  • [Cites] Gastrointest Endosc. 2008 Nov;68(5):911-9 [18561922.001]
  • [Cites] Gastroenterology. 2008 Dec;135(6):2014-8 [19013464.001]
  • [Cites] J Pediatr. 1999 Sep;135(3):390-5 [10484811.001]
  • [Cites] Endoscopy. 1999 Aug;31(6):412-6 [10494676.001]
  • [Cites] Am J Hum Genet. 1955 Sep;7(3):236-63 [13258558.001]
  • [Cites] Dis Colon Rectum. 1959 Sep-Oct;2:465-8 [13839882.001]
  • [Cites] Genet Test. 2004 Winter;8(4):421-30 [15684875.001]
  • [Cites] N Engl J Med. 2005 Mar 17;352(11):1092-102 [15713943.001]
  • [Cites] Am J Med Genet A. 2005 Apr 15;134A(2):212-4 [15690400.001]
  • [Cites] Gastroenterology. 2005 Apr;128(4):1077-80 [15825088.001]
  • [Cites] Am J Gastroenterol. 2005 Jul;100(7):1498-502 [15984971.001]
  • [Cites] Dis Colon Rectum. 2005 Aug;48(8):1528-34 [15906134.001]
  • [Cites] Biochem Soc Trans. 2005 Aug;33(Pt 4):679-83 [16042573.001]
  • [Cites] Am J Med Genet A. 2006 Feb 1;140(3):200-4 [16411234.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Feb;15(2):312-4 [16492921.001]
  • [Cites] Br J Surg. 2006 Apr;93(4):407-17 [16511903.001]
  • [Cites] Int J Cancer. 2006 Aug 15;119(4):807-14 [16557584.001]
  • [Cites] Gut. 1999 Dec;45(6):829-33 [10562580.001]
  • [Cites] Nucleic Acids Res. 2000 Mar 15;28(6):1355-64 [10684930.001]
  • [Cites] J Clin Oncol. 2000 May;18(9):1967-79 [10784639.001]
  • [Cites] N Engl J Med. 2000 Jun 29;342(26):1946-52 [10874062.001]
  • [Cites] Dis Colon Rectum. 2000 Jul;43(7):893-8; discussion 898-902 [10910233.001]
  • [Cites] Am J Pathol. 2000 Sep;157(3):747-54 [10980114.001]
  • [Cites] Gastroenterology. 2000 Dec;119(6):1454-60 [11113066.001]
  • [Cites] Ann Surg. 2001 Mar;233(3):360-4 [11224623.001]
  • [Cites] Arch Ophthalmol. 2001 Apr;119(4):597-602 [11296028.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 May 1;50(1):121-5 [11316554.001]
  • [Cites] Gastroenterology. 2001 Jul;121(1):195-7 [11438508.001]
  • [Cites] J Wound Ostomy Continence Nurs. 2001 Jul;28(4):184-9 [11452254.001]
  • [Cites] Nat Genet. 2002 Feb;30(2):227-32 [11818965.001]
  • [Cites] Gastroenterology. 2002 Mar;122(3):641-5 [11874996.001]
  • [Cites] N Engl J Med. 2002 Apr 4;346(14):1054-9 [11932472.001]
  • [Cites] Gut. 2002 May;50(5):636-41 [11950808.001]
  • [Cites] J Gastrointest Surg. 2002 Jan-Feb;6(1):82-7 [11986022.001]
  • [Cites] Hum Mutat. 2002 Jun;19(6):664 [12007223.001]
  • [Cites] Gut. 2002 Sep;51(3):446-9 [12171972.001]
  • [Cites] J Clin Microbiol. 2002 Oct;40(10):3565-71 [12354847.001]
  • [Cites] Dis Colon Rectum. 2002 Nov;45(11):1496-502 [12432298.001]
  • [Cites] Br J Surg. 2003 Feb;90(2):227-31 [12555301.001]
  • [Cites] N Engl J Med. 2003 Feb 27;348(9):791-9 [12606733.001]
  • [Cites] Dis Colon Rectum. 2003 Apr;46(4):481-5 [12682541.001]
  • [Cites] Cancer Res. 2003 Apr 15;63(8):1752-5 [12702556.001]
  • [Cites] Gastroenterology. 2003 May;124(6):1574-94 [12761718.001]
  • [Cites] Cancer Res. 2003 Jul 15;63(14):3891-3 [12873979.001]
  • [Cites] Dis Colon Rectum. 2003 Oct;46(10):1418-23; discussion 1422-3 [14530685.001]
  • [Cites] Fam Cancer. 2001;1(2):75-82 [14574001.001]
  • [Cites] Fam Cancer. 2003;2(1):43-55 [14574166.001]
  • [Cites] Clin Cancer Res. 2003 Oct 15;9(13):4756-60 [14581346.001]
  • [Cites] Dig Dis Sci. 2003 Oct;48(10):1998-2002 [14627347.001]
  • [Cites] Genet Test. 2003 Fall;7(3):189-94 [14641994.001]
  • [Cites] Cancer. 2004 Feb 1;100(3):612-20 [14745880.001]
  • [Cites] Gut. 2004 Mar;53(3):381-6 [14960520.001]
  • [Cites] Hum Mutat. 2003 Jun;21(6):655-6 [14961559.001]
  • [Cites] Int J Cancer. 2004 May 1;109(5):680-4 [14999774.001]
  • [Cites] Oncogene. 2004 Sep 2;23(40):6820-2 [15273732.001]
  • [Cites] Gastroenterology. 2004 Sep;127(3):838-44 [15362039.001]
  • [Cites] Acta Chir Scand. 1975;141(3):228-37 [1166747.001]
  • [Cites] Am J Hum Genet. 1988 Feb;42(2):290-6 [3422541.001]
  • [Cites] Lancet. 1989 Sep 30;2(8666):783-5 [2571019.001]
  • [Cites] Ann Med. 1989 Aug;21(4):299-307 [2551351.001]
  • [Cites] Gastroenterology. 1991 Jun;100(6):1658-64 [1673441.001]
  • [Cites] Cell. 1991 Aug 9;66(3):589-600 [1651174.001]
  • [Cites] Science. 1991 Aug 9;253(5020):665-9 [1651563.001]
  • [Cites] Nature. 1992 Sep 17;359(6392):235-7 [1528264.001]
  • [Cites] N Engl J Med. 1993 May 6;328(18):1313-6 [8385741.001]
  • [Cites] Am J Hum Genet. 1993 Jul;53(1):33-45 [8317496.001]
  • (PMID = 19822006.001).
  • [ISSN] 1750-1172
  • [Journal-full-title] Orphanet journal of rare diseases
  • [ISO-abbreviation] Orphanet J Rare Dis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 114
  • [Other-IDs] NLM/ PMC2772987
  •  go-up   go-down


2. Zorzi M, Baracco S, Fedato C, Grazzini G, Naldoni C, Sassoli dé Bianchi P, Senore C, Visioli CB, Cogo C: Screening for colorectal cancer in Italy: 2008 survey. Epidemiol Prev; 2010 Sep-Dec;34(5-6 Suppl 4):53-72
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Among the 665,264 subjects attending screening for the first time, the detection rate (DR) per 1,000 screened subjects was 2.7 for invasive cancer and 13.1 for advanced adenomas (AA, adenomas with a diameter ≥1 cm, with villous/ tubulo-villous type or with high-grade dysplasia).
  • The DR of cancer and adenomas increased with age and was higher among males.
  • Many programmes reported some difficulties in guaranteeing TC in the appropriate time frame to FOBT+ subjects: in 16.0% of cases the waiting time was longer than two months.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21220837.001).
  • [ISSN] 1120-9763
  • [Journal-full-title] Epidemiologia e prevenzione
  • [ISO-abbreviation] Epidemiol Prev
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


3. Zorzi M, Fedato C, Naldoni C, Sassatelli R, Sassoli De' Bianchi P, Senore C, Visioli CB, Cogo C: Screening for colorectal cancer in Italy: 2007 survey. Epidemiol Prev; 2009 May-Jun;33(3 Suppl 2):57-74
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the South of Italy and Islands only one new programme was activated in 2007, while two others were stopped, with a decline of theoretical extension from 10% to 7%.
  • Among the 914,029 subjects attending screening for the first time, the detection rate (DR) per 1,000 screened subjects was 2.7 for invasive cancer and 12.2 for advanced adenomas (AA, adenomas with a diameter >/=1 cm, with villous/tubulovillous type or with high-grade dysplasia).
  • The DR of cancer and adenomas increased with age and was higher among males; 25% of screen-detected cancers were in TNM stage III+.
  • Many programmes reported some difficulties in guaranteeing TC in the appropriate time frame to SOF+ subjects: in 23.9% of cases the waiting time was longer than two months.
  • [MeSH-major] Adenoma / diagnosis. Carcinoma / diagnosis. Colorectal Neoplasms / diagnosis. Mass Screening / statistics & numerical data

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19776487.001).
  • [ISSN] 1120-9763
  • [Journal-full-title] Epidemiologia e prevenzione
  • [ISO-abbreviation] Epidemiol Prev
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


Advertisement
4. Bechmann LP, Hilgard P, Frilling A, Schumacher B, Baba HA, Gerken G, Zoepf T: Successful photodynamic therapy for biliary papillomatosis: a case report. World J Gastroenterol; 2008 Jul 14;14(26):4234-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful photodynamic therapy for biliary papillomatosis: a case report.
  • Papillomatosis of the bile duct is a rare disease with a high risk of malignant transformation.
  • A previously healthy 65-years old male developed jaundice and right upper abdominal quadrant pain in 1996.
  • A villous adenoma of the distal bile duct was diagnosed.
  • A Whipple procedure was performed.
  • Another adenoma was found in the right hepatic duct resulting in a right hepatectomy.
  • Two years later the patient again developed cholestasis.
  • After drainage of the left hepatic duct with a percutaneous transhepatic cholangial drainage (PTCD) catheter, a recurrent biliary adenomatosis was diagnosed by cholangioscopy.
  • As there was no surgical option left, the patient received photodynamic therapy (PDT) for the recurrent biliary papillomatosis.
  • Three mo after he received further photodynamic therapies, the bile duct epithelium appeared normal and the patient had no signs of adenomatosis, both macroscopically and histologically.
  • The follow-up cholangioscopy in late 2005 revealed only a small papilloma without the need for intervention.
  • Thus, PDT might be a sufficient therapeutic option for recurrent papillomatosis patients with no significant side effects.
  • [MeSH-major] Bile Duct Neoplasms / drug therapy. Papilloma / drug therapy. Photochemotherapy

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Surg. 1996 Dec;83(12):1715-6 [9038549.001]
  • [Cites] Chirurg. 1996 Jan;67(1):93-7 [8851683.001]
  • [Cites] Gastrointest Endosc. 1997 Sep;46(3):237-43 [9378211.001]
  • [Cites] Gastrointest Endosc Clin N Am. 2005 Jul;15(3):377-97, vii [15990048.001]
  • [Cites] Am J Gastroenterol. 2005 Nov;100(11):2426-30 [16279895.001]
  • [Cites] Can J Gastroenterol. 2005 Dec;19(12):731-3 [16341314.001]
  • [Cites] Cancer Control. 2001 Jul-Aug;8(4):337-43 [11483887.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2000;7(6):542-50 [11180885.001]
  • [Cites] Am J Gastroenterol. 2001 Jul;96(7):2093-7 [11467637.001]
  • [Cites] J Hepatol. 2001 Oct;35(4):542-3 [11682045.001]
  • [Cites] Gastrointest Endosc. 2001 Dec;54(6):763-6 [11726858.001]
  • [Cites] Surg Today. 2003;33(10):781-4 [14513330.001]
  • [Cites] Gastroenterology. 2003 Nov;125(5):1355-63 [14598251.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2003;10(5):390-5 [14598142.001]
  • [Cites] Curr Opin Pulm Med. 2004 Jul;10(4):256-60 [15220748.001]
  • [Cites] Gastrointest Endosc. 2004 Jul;60(1):68-75 [15229428.001]
  • [Cites] Curr Pharm Biotechnol. 2004 Aug;5(4):397-408 [15320770.001]
  • [Cites] Nurs Clin North Am. 1990 Sep;25(3):725-38 [2199943.001]
  • [Cites] Arch Surg. 1991 Jan;126(1):111-3 [1824676.001]
  • [Cites] Aust N Z J Surg. 1997 Sep;67(9):664-6 [9322709.001]
  • (PMID = 18636672.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2725388
  •  go-up   go-down


5. Emrich J, Niemeyer C: [The secreting villous adenoma as a rare cause of acute renal failure]. Med Klin (Munich); 2002 Oct 15;97(10):619-23

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The secreting villous adenoma as a rare cause of acute renal failure].
  • [Transliterated title] Das sezernierende villöse Adenom als seltene Ursache einer akuten Niereninsuffizienz.
  • BACKGROUND: Using a typical case the symptomatology, the clinical course, the diagnostics with its difficulties as well as the therapy of the rare secreting villous adenoma with severe electrolyte and fluid depletion syndrome are described.
  • By an increase of the mucous volume together with an exhaustion of the physiological compensation mechanisms a life-threatening condition with severe electrolyte and fluid loss as well as acute prerenal failure develops, which can lead to difficulties in the diagnosis finding.
  • Therefore, especially in case of a triade of prerenal failure, electrolyte disorder and chronic diarrhea, the existence of an intestinal villous adenoma should be considered.
  • TREATMENT: After restoration of the homeostasis, the surgical removal of the infested intestine section should be the first aim, in order to eliminate the chronic electrolyte and fluid loss and detect or prevent a malignant degeneration.
  • Only in exempt cases an endoscopic treatment or a drug therapy with indometacin can alternatively be considered.
  • An untreated secreting villous adenoma on the other side shows a mortality of 100%.
  • [MeSH-major] Acute Kidney Injury / etiology. Adenoma, Villous / secretion. Colonic Neoplasms / secretion

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12386796.001).
  • [ISSN] 0723-5003
  • [Journal-full-title] Medizinische Klinik (Munich, Germany : 1983)
  • [ISO-abbreviation] Med. Klin. (Munich)
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


6. Cruz-Correa M, Hylind LM, Romans KE, Booker SV, Giardiello FM: Long-term treatment with sulindac in familial adenomatous polyposis: a prospective cohort study. Gastroenterology; 2002 Mar;122(3):641-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term treatment with sulindac in familial adenomatous polyposis: a prospective cohort study.
  • Sulindac, a nonsteroidal anti-inflammatory drug, causes regression of colorectal adenomas in the retained rectal segment of FAP patients, although long-term use of this therapy has not been studied.
  • We evaluated the long-term effectiveness and toxicity of sulindac in attempting to maintain retained rectal segments free of adenomas.
  • Number, size, and histologic grade of polyps, side effects, and medication compliance were assessed every 4 months.
  • Prevention of recurrence of higher-grade adenomas (tubulovillous, villous adenomas) was also observed (P = 0.004).
  • At 35 months of follow-up, 1 patient developed stage III cancer in the rectal stump.
  • CONCLUSIONS: Long-term use of sulindac seems to be effective in reducing polyp number and preventing recurrence of higher-grade adenomas in the retained rectal segment of most FAP patients.
  • [MeSH-major] Adenomatous Polyposis Coli / drug therapy. Anti-Inflammatory Agents, Non-Steroidal / administration & dosage. Sulindac / administration & dosage
  • [MeSH-minor] Adult. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / prevention & control. Prospective Studies. Rectum / pathology

  • Genetic Alliance. consumer health - Familial Adenomatous Polyposis (FAP).
  • Genetic Alliance. consumer health - Familial Polyposis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11874996.001).
  • [ISSN] 0016-5085
  • [Journal-full-title] Gastroenterology
  • [ISO-abbreviation] Gastroenterology
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 184SNS8VUH / Sulindac
  •  go-up   go-down


7. Riojas MA, Guo M, Glöckner SC, Machida EO, Baylin SB, Ahuja N: Methylation-induced silencing of ASC/TMS1, a pro-apoptotic gene, is a late-stage event in colorectal cancer. Cancer Biol Ther; 2007 Nov;6(11):1710-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The methylation status of ASC/TMS1 was analyzed in a series of colorectal cancer (CRC) cell lines, adenomas and primary colorectal cancers and normal colorectal tissue samples using methylation-specific PCR (MSP).
  • RT-PCR showed absence of mRNA expression in these same cell lines, and expression was restored after treatment with the demethylating drug 5-aza-2'-deoxyazacytidine.
  • The two unmethylated cell lines showed ASC/TMS1 mRNA expression both before and after treatment with 5-aza-2'-deoxyazacytidine.
  • Methylation was seen in 20 of 115 (17%) of primary colorectal cancer specimens, but no methylation was seen in 30 colorectal adenomas and 11 normal colorectal tissue samples.
  • Methylation status of ASC/TMS1 was correlated with a series of clinicopathological variables using multivariate analysis.
  • Methylation of ASC/TMS1 was more common in right-sided tumors (p = 0.02), concordant with hMLH1 methylation (p = 0.03) and is a late stage event, occurring in 0 of 18 tubular adenomas, 0 of 12 villous adenomas, 2 of 44 (5%) Stage 1 cancers, 8 of 31 (26%) Stage 2 cancers, 8 of 21 (38%) Stage 3 cancers and 2 of 19 (11%) Stage 4 cancers.
  • Methylation of ASC/TMS1 appears to be a late-stage event in colorectal carcinogenesis associated with invasive carcinomas but not with normal colorectal tissue or colorectal adenomas.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17986858.001).
  • [ISSN] 1555-8576
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cytoskeletal Proteins; 0 / PYCARD protein, human; 0 / RNA, Messenger; 0 / Tumor Necrosis Factor-alpha
  •  go-up   go-down


8. Ortega Carnicer J, Ambrós Checa A, Diarte De Miguel J: [Acute pancreatitis, acute kidney failure, metformin intoxication and villous rectal adenoma]. Med Intensiva; 2006 Nov;30(8):409-10
Hazardous Substances Data Bank. METFORMIN HYDROCHLORIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acute pancreatitis, acute kidney failure, metformin intoxication and villous rectal adenoma].
  • [Transliterated title] Pancreatitis aguda, insuficiencia renal aguda, intoxicación por metformina y adenoma velloso rectal.

  • Genetic Alliance. consumer health - Pancreatitis.
  • MedlinePlus Health Information. consumer health - Diabetes Medicines.
  • MedlinePlus Health Information. consumer health - Pancreatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17129542.001).
  • [ISSN] 0210-5691
  • [Journal-full-title] Medicina intensiva
  • [ISO-abbreviation] Med Intensiva
  • [Language] SPA
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Hypoglycemic Agents; 9100L32L2N / Metformin
  •  go-up   go-down


9. Cascón Fonseca LF, Guerrero Gallego J, Balongo de la Vega A: [Three cases of villous adenoma of the Vater papilla]. Gastroenterol Hepatol; 2000 Apr;23(4):174-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Three cases of villous adenoma of the Vater papilla].
  • [Transliterated title] Tres casos de adenoma velloso de papila de Vater.
  • A series of three cases of villous adenoma of the papilla of Vater is reported.
  • In two cases, the pathological diagnosis made before, during and after surgery was of benign villous adenoma.
  • In the third case, the diagnosis made before and during surgery was of adenoma but in the postsurgical examination a macro-invading carcinoma was found.
  • Further endoscopic exploration revealed a recurrent villous adenoma and further surgery was carried out.
  • Total resection, rather than a duodenopancreatectomy, was performed due to the length of time from detection of the recurrence until the second operation as well as to the small size of the recurrent tumor in the surgical examination.
  • [MeSH-major] Adenoma, Villous / pathology. Ampulla of Vater. Common Bile Duct Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10863858.001).
  • [ISSN] 0210-5705
  • [Journal-full-title] Gastroenterología y hepatología
  • [ISO-abbreviation] Gastroenterol Hepatol
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] SPAIN
  •  go-up   go-down


10. Franklin ME Jr, Díaz-E JA, Abrego D, Parra-Dávila E, Glass JL: Laparoscopic-assisted colonoscopic polypectomy: the Texas Endosurgery Institute experience. Dis Colon Rectum; 2000 Sep;43(9):1246-9
Hazardous Substances Data Bank. ACETAMINOPHEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: From May 1990 to September 1999 laparoscopic-monitored colonic polypectomies were performed in 47 patients, with a total of 60 polyps being removed.
  • If the pathologic evaluation indicates malignancy then a segmental resection may be performed, otherwise the patients are decompressed and fed within a short time before discharge.
  • The most common histopathologic diagnosis was tubulovillous adenoma in 28 polyps followed by villous adenoma in 11 polyps.
  • This less invasive procedure yields recovery times similar to that of colonoscopy alone, and the potential complications of a segmental resection are avoided.
  • [MeSH-minor] Acetaminophen / therapeutic use. Adenoma, Villous / surgery. Aged. Analgesics, Non-Narcotic / therapeutic use. Colonic Neoplasms / surgery. Female. Humans. Male. Pain, Postoperative / drug therapy

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11005491.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Analgesics, Non-Narcotic; 362O9ITL9D / Acetaminophen
  •  go-up   go-down


11. Reichart M, Busch OR, Bruno MJ, Van Lanschot JJ: Black esophagus: a view in the dark. Dis Esophagus; 2000;13(4):311-3
Hazardous Substances Data Bank. OMEPRAZOLE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 73-year-old man had a low anterior resection for a villous adenoma in the rectosigmoid.
  • On the 4th day after surgery, he suddenly developed severe interscapular pain.
  • With conservative treatment, including proton pump inhibition, he recovered completely.

  • MedlinePlus Health Information. consumer health - Esophagus Disorders.
  • Hazardous Substances Data Bank. SUCRALFATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11284980.001).
  • [ISSN] 1120-8694
  • [Journal-full-title] Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  • [ISO-abbreviation] Dis. Esophagus
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Ulcer Agents; 0 / Proton Pump Inhibitors; 54182-58-0 / Sucralfate; KG60484QX9 / Omeprazole
  •  go-up   go-down






Advertisement